Skip to main content
You are the owner of this article.
You have permission to edit this article.
Cellular Logistics, Cellular Dynamics scientists to study heart treatment in pigs

Cellular Logistics, Cellular Dynamics scientists to study heart treatment in pigs

stem cell research

A researcher prepares cell samples for analysis at Fujifilm Cellular Dynamics, a stem cell research company in Madison. 

UW-Madison researchers involved in two Madison-based stem cell companies have received a federal grant to test experimental therapies for heart failure in pigs.

The $765,000 grant, announced last week, will allow Dr. Amish Raval, co-founder of Cellular Logistics, and Dr. Tim Kamp, a founder of and consultant to Fujifilm Cellular Dynamics Inc., or FCDI, to test two related treatments on four groups of pigs after heart attacks.

Dr. Amish Raval


More than 5 million Americans suffer from heart failure each year, according to the Centers for Disease Control and Prevention, typically after heart attacks damage heart muscle cells and impair the heart’s ability to pump blood.

Injections of adult stem cells have failed to adequately repair damaged hearts because the cells wash out of the heart or fail to develop into specialized cells called cardiomyocytes, Kamp said in a university statement.

Dr. Tim Kamp


The study in pigs will use a fabric-like matrix developed by Cellular Logistics, designed to hold cells in place, along with early-stage heart muscle cells derived from stem cells, produced by FCDI. The matrix may replenish scarred heart tissue to become more hospitable to the replacement heart muscle cells through chemical and mechanical signaling, Kamp said.

One group of pigs will receive the matrix and the early-stage heart cells, and one group won’t get either treatment. Each of the other two groups will get only one of the treatments.

If the combination is effective, the researchers plan to apply to the Food and Drug Administration to begin human trials, Raval said.

Cellular Logistics, established in 2016, has found that in rat hearts, an injection of the heart stem cell combination has shown “greater than 80% retention after 24 hours,” according to CEO Alex Vodenlich.

The company’s matrix technology, called Tandem HF, was discovered by chief science officer Eric Schmuck in Raval’s research lab at UW-Madison.

Be the first to know

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

The $21 million facility, next to the company's headquarters at University Research Park, will meet the Food and Drug Administration’s strict requirements for Good Manufacturing Practice. It will be at least 1,000 times cleaner than a regular lab, allowing production of cells for clinical trials.

Get up-to-the-minute news sent straight to your device.


News Alerts

Badger Sports

Breaking News